Important advances in oncology最新文献

{"title":"The role of p53 in cell-cycle control and apoptosis: implications for cancer.","authors":"C J Leonard, C E Canman, M B Kastan","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"33-42"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18677001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alteration of signal transduction in T cells from cancer patients.","authors":"A. Ochoa, D. Longo","doi":"10.1007/978-1-4612-2536-2_7","DOIUrl":"https://doi.org/10.1007/978-1-4612-2536-2_7","url":null,"abstract":"","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":"1 1","pages":"43-54"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50952526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strontium 89 in the treatment of bony metastases.","authors":"A T Porter, E Ben-Josef","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"87-94"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18551478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiosurgery for the treatment of intracranial lesions.","authors":"J S Loeffler, D A Larson, D C Shrieve, J C Flickinger","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"141-56"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18676991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-12: potential role in cancer therapy.","authors":"M J Brunda,&nbsp;M K Gately","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>IL-12 is a heterodimeric cytokine that promotes cell-mediated immunity through its regulatory effects on T and NK cells. IL-12 produced endogenously in response to various microbial agents likely plays a role in the host response to infection by intracellular pathogens, and administration of rIL-12 to mice has bee shown to have dramatic therapeutic effects in a number of tumor models and models of infectious diseases. The relatively long serum half-life of IL-12 compared to other lower molecular weight cytokines such as IL-2 should permit more flexibility in dose scheduling. At doses which are efficacious in murine tumor models, IL-12 has been well tolerated. Phase I clinical trials with IL-12 in the treatment of human malignancies have recently been initiated. The results of such studies are required to determine whether the therapeutic potential IL-12 has displayed in murine disease models can be translated into clinical utility in man.</p>","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"3-18"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18677000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A practical approach to the pathology of lymphoid neoplasms: a revised European-American classification from the International Lymphoma Study Group.","authors":"N L Harris","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This formulation includes a number of disease entities which may alarm those who believe that a lymphoma classification must be simple. The fact remains that these are the tumors that pathologists are seeing and diagnosing, and oncologists must be prepared to deal with them. If several morphologically, immunologically and genetically distinct neoplasms prove to respond identically to currently available treatment, the can be \"lumped\" for the purposes of clinical treatment selection (see Table 11-3). However, if new forms of treatment become available, particularly if these are directed against antigenic or genetic features, it will be important to recognize and study each disease separately. This study should be regarded as a preliminary effort to develop a consensus on lymphoma categorization, and constitutes merely a framework for further study. The ILSG has not attempted to determine the reproducibility of diagnosis of the various categories, either among different pathologists or by the same pathologist over time. No prior tumor classification has been based on reproducibility and when such studies have been done with existing classifications of lymphoma, they have shown disappointing results. 1,35,119 It is likely that recognition of clearly defined entities, which have characteristic immunophenotypes and in some cases genetic features, as well a characteristics morphology, will facilitate reproducibility among pathologists.189 Formal reproducibility studies should be undertaken, and should in general be a more frequent activity in the pathologic diagnosis of tumors. The ILSG does not have the resources to make a systematic attempt to determine the utility of these histologically and immunologically defined categories in predicting clinical outcome. The task of the pathologist is to attempt to define diseases by morphologic and other criteria applied to tissue specimens, and this has been the goal of the current endeavor. The clinical information about the different entities is taken from studies already published, which clearly show that each of the entities has distinctive clinical behavior, even if distinctive treatments are not currently available. The joint task of clinical oncologist and hematopathologists now is to undertake systematic application of the criteria presented here to defined groups of patients, to determine whether the newly-recognized categories will help to further stratify treatment response and outcome in clinical trials. Several members of the ILSG have already begun to review cases in cooperative group trials, and have found the recognition of these entities within broad Working Formulation categories can have prognostic implications (Grogan, T and Banks, PM, unpublished data from the Southwest Oncology Group [SWOG]).(ABSTRACT TRUNCATED AT 400 WORDS)</p>","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"111-40"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18676990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the sphingomyelin pathway and protein kinase C in radiation-induced cell kill.","authors":"Z Fuks,&nbsp;A Haimovitz-Friedman,&nbsp;R N Kolesnick","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"19-31"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18676995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alteration of signal transduction in T cells from cancer patients.","authors":"A C Ochoa,&nbsp;D L Longo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The progressive growth of tumor induces a major alteration in the immune response which could have significant deleterious consequences on the outcome of immunotherapeutic strategies. A more complete understanding of the mechanisms involved and the clinical consequences of these alterations is necessary to determine the importance of such changes. It is possible however, that the analysis of the TCR sigma chain or other signal transduction elements can be a more informative way to monitor the therapeutic effects of a particular treatment than the functional immunologic assays on peripheral blood lymphocytes used presently. Ultimately understanding this phenomenon could help determine the treatment approaches that would prevent or reverse the state of altered immune response, allowing for the development of more effective cancer treatments. It is clear that there are a number of barriers to successful immunotherapy (Table 4-1). Each difficulty has a number of potential solutions. It seem likely that as each of these known barriers is overcome, a larger number of patients will benefit than do now from the current generation of treatment approaches. Of course, it is also likely that there are additional barriers to success yet to be uncovered. It is only through careful observation and monitoring of the clinical effects of our interventions that the remaining obstacles will be defined. And it is only through the close interaction of the laboratory and the clinic that novel solutions will be devised.</p>","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"43-54"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18677002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiolabeled antibody therapy of lymphomas.","authors":"O W Press,&nbsp;F R Appelbaum,&nbsp;J F Eary,&nbsp;I D Bernstein","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"157-71"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18676992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tamoxifen for the prevention of breast cancer: yes.","authors":"V G Vogel,&nbsp;M Saenz","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"187-200"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18676994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}